Även europeiska läkemedelsmyndigheten positiv till Corlines planerade fas 2-studie
April 08, 2020 07:13 ET
|
Corline Biomedical AB
Den 11 mars 2020 var Corline inbjudet till rådgivningsmöte (Protocol Assistance) med den europeiska läkemedelsmyndigheten EMA för att diskutera bolagets planerade fas 2-studie för Renaparin®. Bolaget...
SUNSTOCK, INC. ANNOUNCES FULL SETTLEMENT OF ALL OUTSTANDING CONVERTIBLE DEBTS
February 18, 2020 09:00 ET
|
Sunstock, Inc.
SACRAMENTO, CA, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Sunstock, Inc. (“Sunstock” or the “Company”) (OTC Pink: SSOK) announces the full settlement of all corporate outstanding convertible debts. Thus,...
L'agence européenne du médicament accepte le dossier de demande d'enregistrement réglementaire de Lumoxiti dans la leucémie à tricholeucocytes en rechute ou réfractaire
January 02, 2020 01:00 ET
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que l’Agence Européenne du Médicament (EMA) a accepté le dossier de...
The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
January 02, 2020 01:00 ET
|
INNATE PHARMA
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization...
The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia
January 02, 2020 01:00 ET
|
INNATE PHARMA
MARSEILLE, France, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines...
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
September 13, 2019 09:00 ET
|
Auris Medical AG
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
July 29, 2019 07:00 ET
|
ProQR Therapeutics N.V.
Access based on positive interim analysis of clinical data as well as preclinical data to date PRIME designation provides a pathway for frequent and early interactions with the EMA aimed at...
VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac®
June 17, 2019 06:00 ET
|
VBI Vaccines, Inc.
Both co-primary endpoints successfully met – including non-inferiority in all adults age ≥18 years, and superiority in adults age ≥ 45 yearsSeroprotection rates four weeks post-3rd vaccination of...
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®
June 16, 2019 12:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA
March 25, 2019 10:00 ET
|
Biofrontera AG
Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...